Individuals With Chronic Kidney Disease Qualifying for SGLT-2 Inhibitors in the United States and EMPA-KIDNEY Generalizability
Authors:
- Nicholas ChiuNCNicholas Chiu
- Rahul AggarwalRARahul Aggarwal
- Leonard ChiuLCLeonard Chiu
- Muthiah VaduganathanMVMuthiah Vaduganathan
- Gregg C. FonarowGFGregg C. Fonarow
- Deepak L. BhattDBDeepak L. Bhatt
Open Access
- 24 May 2023
- journal article
- Published by Elsevier in JACC: Advances
- Vol. 2 (4) , 100349
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Empagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2023
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsThe Lancet, 2022
- Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019